N-[2-butoxy-4,5-dihydroxy-6-(hydroxymethyl)-3-oxanyl]acetamide | 94536-37-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[2-butoxy-4,5-dihydroxy-6-(hydroxymethyl)-3-oxanyl]acetamide
• 英文别名: N-[2-butoxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• CAS: 94536-37-5
• 化学式: C₁₂H₂₃NO₆
• 分子量: 277.31
• InChiKey: VDOSYEAOEHMJQD-UHFFFAOYSA-N

物化性质

• 沸点：
  519℃
• 密度：
  1.164
• 闪点：
  225℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DEO-GLCNAC TRANSFÉRASE (OGT) ET UTILISATIONS DE CEUX-CI
  申请人：HARVARD COLLEGE

  公开号：WO2016004180A1

  公开（公告）日：2016-01-07

  The present invention provides inhibitors of O-GlcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, metabolic diseases, neurodegenerative diseases, proliferative diseases (e.g., cancers), autoimmune diseases, and inflammatory diseases.

  本发明提供了O-葡萄糖基-N-乙酰氨基葡萄糖转移酶的抑制剂。通常，这些抑制剂是喹诺酮-6-磺酰胺。本发明还提供了由此产生的药物组合物及其在糖尿病及其并发症、代谢性疾病、神经退行性疾病、增殖性疾病（例如，癌症）、自身免疫性疾病和炎症性疾病中的使用方法。
• [EN] NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF<br/>[FR] NOUVEAU COMPOSÉ DÉRIVÉ DE MURAMYLE, SYNTHÈSE ET UTILISATIONS ASSOCIÉES
  申请人：BHARAT BIOTECH INT LTD

  公开号：WO2017098529A1

  公开（公告）日：2017-06-15

  The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. R = alkyl (both linear and branched), aryl, substituted aryl, alkoxy alkyl Wherein, R can be both linear and branched alkyl, aryl, substituted aryl and alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.

  这项发明涉及结构式-VIII的新型Muramyl Dipeptide（MDP）衍生物化合物，以及用于合成的过程、合成中使用的中间体和其用途。其中，R = 烷基（线性和支链）、芳基、取代芳基、烷氧基烷基。其中，R可以是线性和支链烷基、芳基、取代芳基和烷氧基烷基。这些化合物具有出色的药理特性，特别是作为疫苗配方中的辅助免疫调节特性。这些化合物在疫苗中特别有用作为辅助剂。
• Modified oligonucleotides and compound that can be used for synthesizing same
  申请人：GUANGZHOU RIBOBIO CO., LTD.

  公开号：US20200369703A1

  公开（公告）日：2020-11-26

  The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleatides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

  本公开涉及生物医学技术领域，特别是涉及改良寡核苷酸和一种可用于合成相同的化合物以及一种修改寡核苷酸的方法。本公开还涉及使用改良寡核苷酸来预防和/或治疗与主体肝脏相关的疾病。
• N-ACETYGLUCOSAMINE DERIVATIVES AND USE THEREOF
  申请人：MIURA Kyoko

  公开号：US20080293673A1

  公开（公告）日：2008-11-27

  The present invention relates to An N-acetylglucosamine derivative represented by the following formula (1), and a hyaluronic acid production promoting agent containing the same and a skin external preparation containing the same: wherein R 1 is a hydrogen atom or an alkyl group having 2 to 18 carbon atoms; R 2 , R 3 , and R 4 are hydrogen atoms or acyl groups having 2 to 18 carbon atoms and may be all the same or different from others; the steric structure at position 1 may be α or β; provided that R 1 , R 2 , R 3 , and R 4 must not be all hydrogen atoms. It is intended to provide an easily available hyaluronic acid production promoting agent and a skin external preparation whereby the production of hyaluronic acid can be promoted in the skin and thus the skin can be maintained in a vital and moist state so that it is expected that the human skin can be prevented from age.

  本发明涉及以下式（1）所表示的N-乙酰葡萄糖氨衍生物，以及含有该衍生物的透明质酸生产促进剂和皮肤外用制剂：其中，R1是氢原子或具有2至18个碳原子的烷基；R2、R3和R4是氢原子或具有2至18个碳原子的酰基，可以全部相同或不同；位置1的立体结构可以是α或β；前提是R1、R2、R3和R4不能全部是氢原子。旨在提供一种易于获得的透明质酸生产促进剂和皮肤外用制剂，通过促进皮肤中透明质酸的产生，从而使皮肤保持活力和湿润状态，预防人体皮肤老化。
• COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US20220324900A1

  公开（公告）日：2022-10-13

  Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.